Acceleron
| Acceleron | |
|---|---|
| legal form | Incorporated |
| ISIN | US00434H1086 |
| founding | 2003 |
| Seat | Cambridge , MA USA |
| management | Habib Dable, President & CEO , Steven Ertel |
| Branch | pharmacy |
| Website | www.acceleronpharma.com |
Acceleron Pharma is an American pharmaceutical company that has been listed on the American technology exchange NASDAQ since 2013 under the label XLRN. It specializes in the research and development of innovative drugs for patients with a wide range of serious and rare diseases ( orphan disease ).
Field of activity
Acceleron works in the fields of hematology , neurology and oncology . It is currently researching the following substances (indications):
- Luspatercept ( MDS , beta thalassemia, and myelofibrosis ),
- Sotatercept (myelofibrosis) and
- Dalantercept ( renal cell carcinoma )
Acceleron is not yet earning any money with products on the market, but primarily receives payments from collaborations, primarily from Celgene .
See also
Web links
Individual evidence
- ↑ a b Investor FAQs , Company WebSite, accessed on May 11, 2017
- ↑ Management , Company WebSite, accessed May 11, 2017
- ↑ Press release from Acceleron: Acceleron Announces Management Change . May 2, 2017. Accessed on May 11, 2017. ( Page no longer available , search in web archives ) Info: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice.
- ^ Acceleron Pharma Inc. News Headlines , NASDAQ News, accessed May 11, 2017
- ↑ Our Company , Company WebSite, accessed May 11, 2017
- ↑ Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes , PM Celgene, May 6, 2017, accessed on May 11, 2017
- ↑ Pipeline , Company WebSite, accessed May 11, 2017
- ^ Partners , Company WebSite, accessed May 11, 2017
- ↑ Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results ( Memento of the original from April 24, 2017 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice. , PM Acceleron, March 1, 2017, accessed May 11, 2011
